Aducanumab and UsAgainstAlzheimer’s

Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab.

Share:

Sign Up for More Information

About Aducanumab

  • Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. Aducanumab does this by promoting clearance of amyloid beta plaques, a hallmark of Alzheimer’s, from the brain. It has the potential to slow the rate of cognitive and functional decline in persons in the earlier stages of Alzheimer’s and may help preserve the cognitive abilities and functions of these patients for a longer time.

  • Aducanumab, which has been developed by Biogen, is currently being reviewed by the Food and Drug Administration, with a decision expected by the first quarter of 2021.

  • If approved, aducanumab would be the first disease-modifying therapy approved for use in the U.S.

  • Aducanumab was studied in people living with early-stage Alzheimer’s disease; it has not been studied in individuals with moderate to severe Alzheimer’s.

Aducanumab and UsAgainstAlzheimer’s

UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab. By delaying the progression for people in the early stages of the disease, this drug therapy will give people more time to live independently and perform daily activities longer.

To people living with the disease and their caregivers, every single day matters. Approval of this drug also would be a powerful sign of hope for people living with Alzheimer’s after years of disappointment.

Reuters interviewed Russ Paulsen, COO at UsA2 in November:

"The pandemic came and it changed everything. We need something to keep people out of nursing homes." (Read the full article here.)

Russ Paulsen

Chief Operating Officer at patient advocacy group UsAgainstAlzheimer’s

UsA2 also believes that FDA approval of aducanumab would have a ripple effect on pharmaceutical innovation that could spark additional investment by other companies in disease-modifying treatments and therapies.

Statements by UsAgainstAlzheimer’s to FDA Advisory Committee:

Resources

  • Resources
    Thumbnail

    Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

  • Resources
    Thumbnail

    Caregiver Perspectives on the Burden and Impact of Agitation in Caring for Loved Ones with Dementia/Alzheimer's Disease

  • Resources
    Thumbnail

    UsAgainstAlzheimer’s Survey #7 on COVID-19 and Alzheimer’s Community Summary of Findings October 2020

  • Resources
    Thumbnail

    COVID-19 Survey #6 Infographic

  • Resources
    Thumbnail

    UsAgainstAlzheimer’s Survey #6 on COVID-19 and Alzheimer’s Community Summary of Findings, September 2020

  • Resources
    Thumbnail

    The fight against Alzheimer’s disease must never stop – not even in the face of the Covid-19 pandemic

    The Covid-19 pandemic and its sequels have taken over most aspects of our lives for the last six months, and all signs point to continued disruption for some more time...

In the News